Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04773678 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
A Phase 2 study, sponsored by Connect Biopharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 322
- Enrollment target
NCT04773678 is a Phase 2 study that has completed, run by Connect Biopharm. The registered enrollment target is 322 participants.
The verdict
NCT04773678, a Phase 2 study, has completed, sponsored by Connect Biopharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 322 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
Interventions
- DRUG Placebo
- DRUG CBP-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04773678
The ClinicalTrials.gov registry entry for NCT04773678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connect Biopharm, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04773678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04773678 about?
NCT04773678 is a clinical study titled "Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation". This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
What is the current status of trial NCT04773678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2021-05-11. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT04773678?
The interventions under investigation include: Placebo (DRUG), CBP-201 (DRUG).
Who is sponsoring clinical trial NCT04773678?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.